| 21.2 -2.02 (-8.7%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 32.64 | 1-year : | 37.86 |
| Resists | First : | 27.95 | Second : | 32.41 |
| Pivot price | 24.63 |
|||
| Supports | First : | 20.72 | Second : | 17.24 |
| MAs | MA(5) : | 22.04 |
MA(20) : | 25.85 |
| MA(100) : | 21.84 |
MA(250) : | 18 |
|
| MACD | MACD : | -1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 15.3 |
D(3) : | 14.4 |
| RSI | RSI(14): 38.2 |
|||
| 52-week | High : | 32.41 | Low : | 9.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AVTE ] has closed above bottom band by 14.6%. Bollinger Bands are 62.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 23.94 - 24.07 | 24.07 - 24.16 |
| Low: | 20.84 - 20.96 | 20.96 - 21.05 |
| Close: | 21.02 - 21.21 | 21.21 - 21.36 |
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Sat, 20 Apr 2024
Insider Selling: Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells 6,853 Shares of Stock - MarketBeat
Fri, 19 Apr 2024
Aerovate Therapeutics exec sells shares worth over $153000 - Investing.com India
Thu, 18 Apr 2024
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) CEO Sells $247,000.00 in Stock - MarketBeat
Sun, 31 Mar 2024
Aerovate Therapeutics (NASDAQ:AVTE) on the Verge of Substantial Growth - TipRanks.com - TipRanks
Wed, 27 Mar 2024
Aerovate Therapeutics Announces Upcoming Investor Presentation Access - TipRanks.com - TipRanks
Wed, 27 Mar 2024
Aerovate Therapeutics Inc (AVTE) has gained 4.60% in a Week, Should You Hold? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 103.5 (%) |
| Shares Short | 993 (K) |
| Shares Short P.Month | 1,010 (K) |
| EPS | -2.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.94 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.8 % |
| Return on Equity (ttm) | -64 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -57 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -7.39 |
| PEG Ratio | 0 |
| Price to Book value | 5.38 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|